Search Bar & Filters
Found 13 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the use of stereotactic radiotherapy SRT as a treatment strategy for patients with oligoprogressive metastatic renal cell carcinoma RCC who are already undergoing systemic therapies. This phase II study focuses on patients whose cancer has progressed in a limited number of sites despite ongoing treatment, aiming to control local tumors and delay the need for additional systemic therapies. The study builds on evidence that SRT can effectively target RCC metastases and may also stimulate the immune system when combined with immunotherapy. The study involves delivering high-dose stereotactic radiotherapy to metastatic sites showing progression in patients receiving systemic therapies such as targeted drugs or immunotherapy. Eligible patients have 1 to 3 progressing metastases in up to 2 organs, with lesions measuring 4 cm or less, and will continue their current systemic treatment while receiving SRT either concurrently or sequentially. This approach aims to locally control progressing tumors and potentially extend the effectiveness of ongoing therapy. Participants will undergo imaging assessments to confirm disease progression and measure tumor response, with follow-up visits to monitor tumor control and treatment side effects. Researchers will evaluate progression-free survival six months after randomization as the primary outcome, along with local and overall control rates and treatment-related adverse events. The study includes monitoring for safety and effectiveness up to 12 months post-treatment, with participants involvement lasting until at least one month after treatment completion.
Actively Recruiting
Non-muscle-invasive bladder cancer NMIBC is a type of bladder tumor that affects the inner lining of the bladder without invading the muscle layer. This research aims to collect and analyze real-world data on how NMIBC is managed and followed up in clinical practice across France. The study seeks to assess the performance of urine tests used to detect tumor recurrence and to understand variations in treatment and patient outcomes. The study is observational and involves collecting medical data from patients being monitored for NMIBC, including results from urine biomarker tests done before biopsies or resections. Urologists participating in the French Urology Association will record findings from regular bladder endoscopic exams and urine test results during routine care visits. Data analysis will focus on the accuracy of urine tests in predicting tumor recurrence and how this varies by tumor characteristics and prior treatments. Participants will have their medical history, treatments, and urine test results entered into a registry at enrollment. During follow-up visits scheduled as part of their personalized care, data on bladder exams and urine tests will be collected. Researchers will evaluate outcomes such as recurrence-free survival and the diagnostic value of urine biomarkers over a five-year period. The study plans to include around 8,000 patients over six years to improve understanding of NMIBC management and follow-up.
Actively Recruiting
Researchers are studying the World Health Organizations Integrated Care for Older People ICOPE program to see if it helps prevent age-related decline in older adults. This study compares the comprehensive ICOPE program with usual care from primary doctors. The goal is to determine if regular screening, personalized care plans, and follow-up can better maintain functions like mobility, cognition, and nutrition in people aged 65 and older living at home. The trial randomly assigns participants to either receive the full ICOPE program or usual care. The ICOPE program includes screening every six months using a digital tool, a thorough assessment of six key functions, a personalized intervention plan, and ongoing follow-up, including phone calls and annual visits over 60 months. After an initial 36-month intervention, all participants receive the ICOPE program during a 24-month extension phase. Participants have annual visits at 12, 24, 36, 48, and 60 months, during which a research nurse collects data while unaware of which group they are in. Phone calls occur between visits to support the care plan and gather information about life events. The primary outcome measured is functional decline at 36 months. The study runs until 2031, with continuous monitoring of participants health and program adherence.
Actively Recruiting
Researchers are conducting a multicenter, phase 3, open-label study to evaluate treatments for patients with newly diagnosed Multiple Myeloma who are eligible for autologous stem cell transplantation ASCT. The study compares the effects of an experimental combination of elranatamab and lenalidomide against the current standard of care, including chemotherapy, ASCT, and maintenance therapies. The purpose is to assess if these new treatment approaches improve outcomes such as minimal residual disease MRD negativity and progression-free survival. Participants will first undergo induction therapy with four cycles of D-VRd daratumumab, bortezomib, lenalidomide, dexamethasone. Then, they will be randomly assigned to one of two consolidation therapies either standard treatment with high-dose chemotherapy and ASCT followed by D-VRd consolidation, or an experimental consolidation with elranatamab and lenalidomide. After consolidation, patients are re-randomized into maintenance therapy groups receiving either daratumumab plus lenalidomide or elranatamab monotherapy for approximately two years, with treatment adjustments based on MRD status. Throughout the study, participants will have scheduled visits for treatment administration, monitoring, and various assessments including blood tests, imaging, and quality of life questionnaires. Researchers will measure key outcomes such as MRD negativity rates, progression-free survival, overall survival, safety, and tolerability over several years. The study also tracks health-related quality of life and adverse events during induction, consolidation, and maintenance phases, with follow-up extending up to 11 years.
Actively Recruiting
This observational study evaluates the Polymer Free Sirolimus Eluting Coronary Stent System, known as the Vivo ISAR, in everyday clinical practice for patients with coronary artery stenosis. The purpose is to collect real-world data on clinical outcomes over a 12-month follow-up period, focusing on patients who receive this stent system as part of their routine care. The study is sponsored by Translumina GmbH and involves standard procedures and medications with known safety profiles. Participants will be treated with the Vivo ISAR stent during percutaneous coronary intervention to improve coronary artery diameter in those experiencing symptoms of ischemic heart disease. The study monitors patients who receive the stent in one or multiple vessels, observing their progress without altering standard care practices. The follow-up extends to 12 months after the procedure to assess various success rates and treatment effects. During the study, participants undergo routine clinical evaluations including assessments of device and procedural success shortly after treatment, and measures of target lesion failure and reperfusion at 12 months. Researchers also evaluate antiplatelet therapy adherence and effectiveness. The total participation involves regular check-ups and data collection to understand long-term outcomes and safety of the Vivo ISAR stent system in typical healthcare settings.
Actively Recruiting
This research aims to evaluate the best way to manage fever in patients with septic shock who require mechanical ventilation and sedation. Septic shock is a severe condition with high mortality, often linked to infections like pneumonia. Fever can increase oxygen use and inflammation, potentially worsening organ failure, but may also slow bacterial and viral growth. Previous pilot studies showed that controlling fever with external cooling improved shock resolution and organ function, though effects on longer-term survival remain unclear. This trial compares two fever management strategies to see which better reduces mortality at 60 days. Participants will be randomly assigned to one of two groups one will receive fever control by external cooling to maintain normal body temperature for 48 hours, and the other will have their fever respected without antipyretic therapy. The study uses covariate-adaptive randomization and includes a subgroup with acute respiratory distress syndrome ARDS. An independent safety committee will monitor serious adverse events, and interim analyses may adjust enrollment based on results. Throughout the study, participants will be monitored for mortality at 60 days as the primary outcome. Secondary measures include organ function scores, days free from ventilators, kidney therapy, vasopressors, and monitoring for complications like shivering, seizures, hypothermia, arrhythmias, infections, ARDS development, and acute kidney injury. The trial spans several years, with detailed assessments during and after treatment to evaluate the impact of fever management strategies on patient outcomes.
Actively Recruiting
Bronchiectasis is a chronic lung condition where parts of the airways are permanently widened, causing mucus buildup, infections, and ongoing inflammation. This study evaluates the long-term use of the SIMEOX medical device at home, combined with remote physiotherapy, to improve quality of life and reduce lung flare-ups in adults with non-cystic fibrosis bronchiectasis. The research compares this approach to enhanced standard care including remote physiotherapy alone. Participants will be randomly assigned to either standard care with remote physiotherapy or to use the SIMEOX device daily at home alongside remote physiotherapy. Remote physiotherapy sessions occur once a month for the first three months and then every three months. The study spans an average of 24 months to assess the effects of adding the SIMEOX device to usual care. During the study, participants will complete quality of life questionnaires and undergo lung function tests at 6, 12, and 24 months. The main outcomes measured include the yearly rate of lung exacerbations and changes in quality of life scores. Researchers will also track hospitalizations, treatment compliance, adverse events, and lung function changes. The long follow-up aims to evaluate the sustained impact of the device and physiotherapy on participants respiratory health.
Actively Recruiting
Researchers are studying a new way to give immunotherapy as maintenance treatment for patients with metastatic non-squamous lung cancer. This phase III clinical trial compares a pulse dosing schedule with a conventional dosing schedule to see if the less frequent pulse dosing is not worse than the standard treatment. The study focuses on pembrolizumab alone or combined with pemetrexed as the maintenance therapy after initial chemotherapy and immunotherapy induction. Participants are randomly assigned to one of two groups. In the Pulse arm, pembrolizumab 200 mg is given every 6 weeks, and pemetrexed 500 mgm is given every 3 weeks if there is no contraindication. In the Control arm, pembrolizumab is given either 200 mg every 3 weeks or 400 mg every 6 weeks, plus pemetrexed 500 mgm every 3 weeks when appropriate. This treatment is given after patients have completed 3 or 4 cycles of induction therapy with pembrolizumab plus platinum and pemetrexed. During the study, participants will be monitored for overall survival over 6 years, along with progression-free survival, response duration, quality of life using several questionnaires, treatment tolerance, and economic factors. Researchers will also perform population pharmacokinetic analyses and study the drugs effect on immune cells. Patients will undergo regular assessments including clinical evaluations and laboratory tests to track treatment effects and safety throughout the study period.
Actively Recruiting
Squamous cell carcinoma of the anus is a rare but increasingly common cancer, often linked to human papillomavirus HPV. For early-stage tumors, combined radiotherapy and chemotherapy with 5FU and mitomycin-C provide good outcomes, but advanced tumors have a poor prognosis with a high relapse rate. Researchers are studying a new approach combining induction chemotherapy with docetaxel, cisplatin, and 5FU mDCF followed by standard chemoradiotherapy to improve treatment results for locally advanced anal cancer T3-4 or N1. This is a randomized phase 3 trial comparing this new strategy to the current standard treatment. The study includes two groups one receives the usual chemoradiotherapy, which involves 33 radiotherapy sessions over 6.5 weeks combined with mitomycin-C and capecitabine chemotherapy taken on radiotherapy days. The other group starts with 4 cycles of mDCF chemotherapy given every two weeks before receiving the same chemoradiotherapy as the control group. Radiotherapy uses intensity-modulated external irradiation with a targeted boost to the tumor and involved lymph nodes. Participants will be followed after treatment with check-ups at 8 weeks, then every 4 months for two years, and every 6 months in the third year. Follow-up includes clinical exams and imaging scans CT and MRI. The main measure of success is disease-related event-free survival two years after treatment. Other outcomes include overall survival, colostomy-free survival, treatment side effects, tumor response, and quality of life. The total study duration for each participant may extend over several years including this follow-up period.
Actively Recruiting
Researchers are studying the Scratch Collapse Test SCT, a reflex used to detect nerve compression in conditions like carpal tunnel syndrome. This study focuses on patients with one-sided carpal tunnel syndrome and aims to analyze muscle response loss using myography after sensory stimulation. Though the SCT is known for showing transient muscle weakness on the affected side, this study will specifically measure this loss of muscle tone and its temporary and one-sided nature. Participants will undergo electromyography, which uses electrodes to measure nerve impulse transmission along the median nerve in both hands for comparison. The SCT involves applying sensory stimulation to the wrist and then testing muscle strength on both sides. The test is expected to show transient muscle tone loss on the affected side only. This is an interventional study focused on diagnostic testing procedures. During the study, patients diagnosed with unilateral carpal tunnel syndrome will have myographic tracings recorded and analyzed to observe changes after sensory stimulation. The main outcome measured is the evolution of these myographic tracings on the day of testing. Participants will be closely monitored for the muscle response changes related to nerve compression. The study will last for a short period focused on these diagnostic evaluations.
1-10 of 13
1